The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program
Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in combination to ribavirin (RBV). Before official reg...
Saved in:
Main Authors: | V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2018-08-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/192 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients
by: D. T. Abdurakhmanov, et al.
Published: (2018-08-01) -
Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)
by: M. V. Mayevskaya, et al.
Published: (2018-08-01) -
Efficacy and safety of 3D-therapy at HCV-related subcompensated liver cirrhosis (genotype 1b)
by: P. O. Bogomolov, et al.
Published: (2018-08-01) -
Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study
by: D. T. Abrurakhmanov, et al.
Published: (2014-07-01) -
Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial)
by: Marina V. Mayevskaya, et al.
Published: (2018-08-01)